Several FDA-approved drugs, such as trastuzumab (Herceptin) for Human Epidermal growth factor Receptor 2 (HER-2) positive breast and stomach cancers and vemurafenib (Zelboraf) for BRAF-mutant metastatic melanoma, exemplify the success of this approach [11,12]. Here, ERBB2 is linked to metastatic melanoma.